BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia

• Principais autores: Jing-dong Zhou (Autor), Ting-juan Zhang (Autor), Zi-jun Xu (Autor), Yu Gu (Autor), Ji-chun Ma (Autor), Xi-xi Li (Autor), Hong Guo (Autor), Xiang-mei Wen (Autor), Wei Zhang (Autor), Lei Yang (Autor), Xing-hui Liu (Autor), Jiang Lin (Autor), Jun Qian (Autor)
• Formato: Livro
• Publicado em: BMC, 2019-06-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Abstract Background BCL2 protein inhibitor venetoclax (ABT-199) has been authorized by Food and Drug Administration for relapsed/refractory chronic lymphoid leukemia with 17p deletion. Although venetoclax/ABT-199 also caused cell death in acute myeloid leukemia (AML), whether it could be applied to...